Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
NA
30 participants
INTERVENTIONAL
2009-05-31
2013-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
30 minute light duration
30 minute treatment with UVX light
riboflavin
riboflavin 0.1% is applied every 2 minutes for 30 minutes
UVX Light
UVX 365 nm wavelength light source is applied with continued application of riboflavin 0.1%
45 minute light duration
45 minute treatment with UVX light
UVX Light
UVX 365 nm wavelength light source is applied with continued application of riboflavin 0.1%
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
riboflavin
riboflavin 0.1% is applied every 2 minutes for 30 minutes
UVX Light
UVX 365 nm wavelength light source is applied with continued application of riboflavin 0.1%
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* corneal ulcer that has produced a descemetocele
* women who are pregnant or breastfeeding
* patients who are immunocompromised or unwilling or unable to comply with a medication regimen
14 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Cornea Research Foundation of America
OTHER
Price Vision Group
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Francis W Price, MD
Role: PRINCIPAL_INVESTIGATOR
Price Vision Group
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Price Vision Group
Indianapolis, Indiana, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Iseli HP, Thiel MA, Hafezi F, Kampmeier J, Seiler T. Ultraviolet A/riboflavin corneal cross-linking for infectious keratitis associated with corneal melts. Cornea. 2008 Jun;27(5):590-4. doi: 10.1097/ICO.0b013e318169d698.
Price MO, Tenkman LR, Schrier A, Fairchild KM, Trokel SL, Price FW Jr. Photoactivated riboflavin treatment of infectious keratitis using collagen cross-linking technology. J Refract Surg. 2012 Oct;28(10):706-13. doi: 10.3928/1081597X-20120921-06.
Davis SA, Bovelle R, Han G, Kwagyan J. Corneal collagen cross-linking for bacterial infectious keratitis. Cochrane Database Syst Rev. 2020 Jun 17;6(6):CD013001. doi: 10.1002/14651858.CD013001.pub2.
Related Links
Access external resources that provide additional context or updates about the study.
Price Vision Group website
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2008-0143
Identifier Type: -
Identifier Source: org_study_id